Bullous Pemphygoid and Novel Therapeutic Approaches

D’Agostino, Giovanni Marco; Rizzetto, Giulio; Marani, Andrea; Marasca, Samuele; Candelora, Matteo; Gambini, Daisy; Gioacchini, Helena; De Simoni, Edoardo; Maurizi, Andrea; Campanati, Anna; Offidani, Annamaria

doi:10.3390/biomedicines10112844

Open AccessReview

Bullous Pemphygoid and Novel Therapeutic Approaches

by

Giovanni Marco D’Agostino

,

Giulio Rizzetto

,

Andrea Marani

,

Samuele Marasca

,

Matteo Candelora

,

Daisy Gambini

,

Helena Gioacchini

,

Edoardo De Simoni

,

Andrea Maurizi

,

Anna Campanati

^*,†

and

Annamaria Offidani

^†

Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Biomedicines 2022, 10(11), 2844; https://doi.org/10.3390/biomedicines10112844

Submission received: 2 October 2022 / Revised: 29 October 2022 / Accepted: 3 November 2022 / Published: 8 November 2022

(This article belongs to the Special Issue Immune-Mediated Skin Diseases: From Pathophysiology to Novel Therapeutic Approaches 2.0)

Download

Browse Figure

Review Reports Versions Notes

Abstract

Bullous pemphigoid is a subepidermal blistering disease associated with autoantibodies (auto-ab) to BP180 and BP230 which affects elderly patients, predominately. Although it is a rare disease, bullous pemphigoid is the most common among the autoimmune bullous skin diseases. Systemic corticosteroids and immunosuppressants represent milestones in the treatment of patients suffering from bullous pemphigoid; however, therapeutic management of patients still represents a clinical challenge, owing to the chronic nature of the disease and to potential adverse effects related to the long-term use of systemic treatments. Recent discoveries on the pathogenesis of bullous pemphigoid have allowed investigation of new target therapies against selective pro-inflammatory mediators. These therapies appear to yield satisfactory results with fewer side effects in cases of refractory disease. The review discusses current evidence on these new therapeutic targets and specific drugs under investigation.

Keywords: bullous pemphigoid; target therapies; biologics; small molecules; novel treatments

Share and Cite

MDPI and ACS Style

D’Agostino, G.M.; Rizzetto, G.; Marani, A.; Marasca, S.; Candelora, M.; Gambini, D.; Gioacchini, H.; De Simoni, E.; Maurizi, A.; Campanati, A.; et al. Bullous Pemphygoid and Novel Therapeutic Approaches. Biomedicines 2022, 10, 2844. https://doi.org/10.3390/biomedicines10112844

AMA Style

D’Agostino GM, Rizzetto G, Marani A, Marasca S, Candelora M, Gambini D, Gioacchini H, De Simoni E, Maurizi A, Campanati A, et al. Bullous Pemphygoid and Novel Therapeutic Approaches. Biomedicines. 2022; 10(11):2844. https://doi.org/10.3390/biomedicines10112844

Chicago/Turabian Style

D’Agostino, Giovanni Marco, Giulio Rizzetto, Andrea Marani, Samuele Marasca, Matteo Candelora, Daisy Gambini, Helena Gioacchini, Edoardo De Simoni, Andrea Maurizi, Anna Campanati, and et al. 2022. "Bullous Pemphygoid and Novel Therapeutic Approaches" Biomedicines 10, no. 11: 2844. https://doi.org/10.3390/biomedicines10112844

APA Style

D’Agostino, G. M., Rizzetto, G., Marani, A., Marasca, S., Candelora, M., Gambini, D., Gioacchini, H., De Simoni, E., Maurizi, A., Campanati, A., & Offidani, A. (2022). Bullous Pemphygoid and Novel Therapeutic Approaches. Biomedicines, 10(11), 2844. https://doi.org/10.3390/biomedicines10112844

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Bullous Pemphygoid and Novel Therapeutic Approaches

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI